Background {#Sec1}
==========

Worldwide, cervical cancer is diagnosed annually in more than 500,000 women and is still a major health problem among women worldwide \[[@CR1]\]. Cervical cancer is preceded by Cervical Intraepithelial Neoplasia (CIN) of the cervix and caused by high risk Human Papilloma Viruses (hrHPV) \[[@CR2]\]. CIN is subdivided in three groups: CIN I mild dysplasia, also known as low grade squamous intraepithelial lesion (LSIL). CIN II is mild dysplasia and CIN III severe dysplasia, both also known as high-grade squamous intraepithelial lesion (HSIL). Persistent hrHPV infection is a prerequisite to develop cervical cancer. About 80% of women will be infected with HPV during their life and most women are able to clear the HPV infections. However, approximately 20% of these women have detectable transient infections and a fraction will subsequently develop to cervical cancer if not treated for these precursor lesions \[[@CR3]\]. With adequate screening and treatment of CIN, cervical cancer can be prevented \[[@CR4]\].

The most commonly used method to treat CIN II-III is Loop Electrosurgical Excision Procedure (LEEP) to prevent possible progression to invasive cancer. Data on recurrent disease after LEEP vary in the literature. Up to 17% of women treated for CIN II-III have residual or may develop recurrent CIN II-III \[[@CR5], [@CR6]\]. Treatment is associated with side effects such as hemorrhage, infection, and stenosis of the cervix, and as well as adverse pregnancy outcomes, such as premature rupture of membranes and premature birth. Re-excision is needed in case of recurrence with an increased risk for adverse events. Especially the adverse obstetrical outcomes are higher after multiple treatments \[[@CR7]--[@CR9]\]. Women treated for CIN also have an increased risk of developing cervical, vaginal and vulvar cancer compared to patients with normal primary smear test results \[[@CR10]--[@CR12]\]. To prevent HPV-related diseases, eradication is preferable to treating recurrences repeatedly \[[@CR13]\]. Recurrence can be monitored by HPV testing.

Many studies have proven the efficacy and safety of the prophylactic HPV vaccine against the development of cervical intraepithelial neoplasia in HPV naïve women \[[@CR14]--[@CR16]\]. In 2013, Kang et al. reported retrospective data that demonstrated possible prevention of CIN II-III recurrence after LEEP treatment when treatment was combined with quadrivalent HPV vaccination. This study showed that 5 patients (2.5%) in the vaccinated group (197 patients) and 18 patients (8.5%) in the unvaccinated group (211 patients) developed recurrent disease after LEEP (relative risk 0.17, 95%CI 0.08--0.36; *P* \< 0.001) related to the vaccine HPV types. Irrespective of HPV vaccine type the recurrence rate was 2.5% (9/360) in the vaccinated group versus 7.2% (27/377) in the unvaccinated group. Multivariate analysis showed that no vaccination after LEEP was an independent risk factor for recurrent CIN II-III (HR = 2.8; 95% confidence interval 1.3--6.0; *P* \< 0.01) \[[@CR17]\]. Previously, Joura et al. concluded from post hoc analysis, women receiving prophylactic HPV vaccine in a randomized setting and treated for HPV related diseases (cervical, vaginal, vulvar) are less likely to develop recurrent lesions compared to those not vaccinated \[[@CR18]\]. There is increasing evidence of an additional vaccine effect after treatment of clinical HPV related anogenital, dermal and oropharyngeal diseases \[[@CR17], [@CR19]--[@CR22]\]. Hypothetically, an increased immune response with increasing levels of antibodies after HPV vaccination might explain the effect. In addition, there ought to be protection against de novo HPV infections \[[@CR23], [@CR24]\]. A randomised controlled trial is lacking on this subject.

In this study, we will compare HPV vaccination with the nonavalent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, and 58) versus placebo (physiological salt solution) vaccination subsequently to LEEP treatment in women without previous treatment for CIN or HPV vaccination. This study is a randomised, double blinded, placebo controlled trial to evaluate the efficacy of the nonavalent HPV vaccine in preventing recurrent CIN II-III after 24 months.

Methods {#Sec2}
=======

Setting and study design {#Sec3}
------------------------

The VACCIN study is a randomised multicenter, double blinded, placebo controlled trial in female patients with histological diagnosed CIN II or CIN III and treated with LEEP. Recruitment of participants will be done from colposcopy clinics in participating centers. After histologic diagnosis of CIN II-III for which a LEEP is necessary, patients will be counselled for participating in this study.

In the Netherlands most women with CIN are detected via population based cervical cancer screening starting at the age of 30 years.

In addition, general practitioners may refer women with intermenstrual or postcoital bleeding. This also includes women younger than those in the national screening program for cervical cancer. When abnormal Pap smears are found, they are referred for colposcopy.

In- and exclusion criteria {#Sec4}
--------------------------

Women are eligible for participation if they are eighteen years old or above, histologically proven CIN II or III and will be treated with a LEEP. Inclusion must be within four weeks after LEEP. Exclusion criteria are: a prior HPV vaccination, invasive carcinoma, immune-compromised women, pregnant women, prior treatment for CIN-lesions, insufficient understanding of the Dutch language or allergic to vaccine components.

Randomisation, blinding and treatment allocation {#Sec5}
------------------------------------------------

Randomisation will be performed through the secure web-based interface Castor EDC (Castor Electronic Data Capture, available at: <https://castoredc.com>). Patients will be randomised to either active study medication, or placebo in a 1:1 ratio. Randomisation will be stratified by age, categorized as being 18 to 29 years, 30 to 44 years, or 45 years and older. Women aged 18 to 29 years are not eligible for routine screening under the national screening program. The second stratum includes women of 30 to 44 years who are of reproductive age and invited for routine testing under the national screening program. The third stratum women of 45 years and older, who are less likely to be fertile. Randomisation will use random permuted blocks of sizes 2 and 4.

Both doctor and patient will be blinded for treatment allocation. The allocated medication will be prepared and distributed by the hospital pharmacy as syringes with identical appearance.

Study objectives and outcome {#Sec6}
----------------------------

The primary objective is:

The efficacy of nonavalent HPV vaccination in women with a CIN II-III lesion who underwent a LEEP in preventing recurrent CIN II-III after at 24 months follow-up.

The secondary objectives are: The recurrence of CIN I-II-III at 6, 12 and 24 months.The effect of HPV vaccination on HPV DNA presence at 6 and 24 months after LEEP.The effect of HPV vaccination on Pap-smear results.Number of LEEP for recurrent CIN.Cost-effectiveness analysis from a societal perspective: intramural and extramural medical costs questionnaire (iMCQ) and productivity cost questionnaire (iPCQ) will be performed at the start of the study, at 2 months and after 24 months.Quality of life will be assessed with quality of life questionnaire: Euroqol 5D-5 L at the start of the study, at 2 months, at 6 months and after 24 months.Side effects and adverse events. One week after each vaccination, a telephonic interview will be performed to ask for side effects after the injection.

The tertiary and long-term objectives are: Cytology result after 5 years by retrieving HPV-test and Pap smear results from the national database of the population based cervical cancer screening program.Cytology result after 10 years by retrieving HPV-test and Pap smear results from the national database of the population based cervical cancer screening program.Vaccination effect on premature delivery and obstetrical complications by comparing the results to a national database on childbirth data.

Interventions {#Sec7}
-------------

Patients eligible for participation will be counselled and receive written information. All patients must provide written informed consent prior to participation. After written consent patients will be randomised to either Nonavalent HPV-vaccine (Gardasil-9®) orPlacebo vaccine (physiological salt solution for injections)

The LEEP should be performed according to guideline for regular care. Preferably, at the day of LEEP the first vaccination should be administered. The first vaccination should be administered at least within 4 weeks after the LEEP. This time window was chosen in particular for logistical reasons, for example with the see and treat method. The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Although studies do not indicate adverse pregnancy outcomes, patients will be asked to use reliable contraceptive during the vaccination period (6 months). Follow-up will be according the Dutch guideline for cervical and vaginal dysplasia (CIN, AIS and VAIN 2015) \[[@CR25]\], (see Fig. [1](#Fig1){ref-type="fig"}: Flowchart study design). One week after each vaccination, telephonic interview is performed to ask for side effect of the injection. Fig. 1Flowchart study design follow-up

Sample size calculations {#Sec8}
------------------------

The sample size calculations have been based on the only publication available at the time of preparing this trial. This retrospective cohort study describes an incidence of 2.5% in women treated with quadrivalent HPV vaccine, against 8.5% in the untreated group (Kang et al., 2013). With a target power of 0.8 and an alpha of 0.050, a total number of 646 patients needs to be recruited into the study if the incidence of CIN II-III at two-year follow-up is 3% in the group receiving active treatment, and 8% in the group receiving placebo. Clinical practice shows that the proportion of women who do not attend follow-up visits in this population is high. Therefore, a loss to follow-up is anticipated of 10 to 15%. To compensate for such attrition, the total number of patients that is to be recruited for the study is rounded to 750 patients in total.

Data collection {#Sec9}
---------------

All data will be collected using an eCRF and by means of electronic questionnaires. The eCRF and questionnaire data will be collected and stored using Castor EDC, which is also used for randomisation. Subject numbers will be assigned sequentially to subjects enrolled in the study. Stored data is only accessible to the principal and coordinating investigator.

The following data and outcome parameters are collected (see also Fig. [2](#Fig2){ref-type="fig"}): Patient characteristics; age, obstetrical history, contraceptive use, condom use complementary to contraceptive, HPV related history, smoking, family planning.Indication for testing, cytology results, KOPAC-classification, HPV genotype, biopsy result.Quality of life questionnaire (Euroqol 5D-5 L) and societal economical costs questionnaire (iPCQ, adjusted iMCQ).Initial Pap smear and HPV test resultsFig. 2Schedule of enrolment, interventions, and assessments VACCIN-study. \* Follow up is according to national guideline, when needed cytology, HPV typing or colposcopy is performed and data is collected between 6 and 24 months. \*\* When result at 24 months is either HPV positive or ≥ PAP2 a colposcopy is performed

1 week follow-up: Side effects of the injection, Result of LEEP (no CIN, CIN I, II or III) and LEEP margins (clear margins or CIN in margins).

2 months follow up: Side effects of the injection.QoL (Euroqol 5D-5 L) and societal economical costs questionnaire (iPCQ, adjusted iMCQ).

6 months follow-up: Cytology results and HPV genotype, QoL (Euroqol 5D-5 L) questionnaire.Side effects of the injection.

24 month follow-up: Cytology results and HPV genotype. When either test is abnormal, colposcopy will be performed and biopsies taken for histologic study endpoint.QoL and societal economical costs questionnaire (iPCQ, adjusted iMCQ).All other cytology test, colposcopy results, LEEP result and HPV genotype test between appointment 6 months and 24 months follow-up if appropriate.Pregnancy during follow-up with obstetrical outcome.

60 and 120 months follow-up: Collection of HPV test and Pap smear result via population screening program and sub sequential treatment.Collection of national database on childbirth data on subsequent pregnancies and the following pregnancy outcomes: gestational age, miscarriages, preterm rupture of membranes.

Statistical analysis {#Sec10}
--------------------

The main analysis for the primary outcome testing the hypothesis of superiority of nonavalent vaccine as compared to placebo, for preventing CIN II-III recurrence after 24 months will be conducted using a χ^2^ test. Outcome measure for the primary outcome is a relative risk with 95% confidence interval.

Relative risks will also be estimated for secondary categorical outcomes, with 95% confidence intervals and χ^2^ or Fisher's exact test for significance. Continuous data will be described using means with standard deviation, or medians with interquartile ranges; t-tests or Mann-Whitney U tests will be used as appropriate. Kaplan-Meier curves will be made for time between LEEP, vaccination with active or placebo and CIN II-III recurrence. The curves will be compared using the log-rank test. Quality of Life will be measured at every visit. They will be assessed with Euroqol 5D-5 L questionnaire. Patients from both groups will be analyzed using generalized linear mixed models.

The cost-effectiveness will be assessed by calculating the incremental cost-effectiveness ratio (ICER), defined as the difference in costs, divided by the average change in effectiveness of the vaccine versus a placebo following LEEP treatment. A Budget impact analysis (BIA) will be performed, in accordance with the principles for good practice for BIA, to address the financial stream of consequences in order to assess the affordability of offering the vaccine following LEEP treatment. BIA will compare the likely impact of replacing LEEP by HPV vaccination on national health plan budgets, on hospital level and on assurance level. From the viewpoint of the government, the broad societal perspective and the 'budgetary framework for care' will be highlighted. A valid framework (Markov model) will give insight into the budget consequences. We will also perform sensitivity analyses and a 'most optimistic versus pessimistic' scenario. If the vaccine has a preventive effect, it will be included in the new national guideline. As a result, the health care insurance can compensate this as regular care.

Discussion {#Sec11}
==========

Prophylactic HPV vaccines are very effective in reducing premalignant lesions of the cervix in HPV negative young women and less so in women up to 25 years of age \[[@CR26]\]. Less clear (i.e. only retrospective studies) are effects of adjuvant vaccination in context of CINII-III treatment in HPV positive women. The results of this prospectively randomized study will demonstrate whether adjuvant vaccination has a positive effect on recurrent CINII-III necessitating a second LEEP. This study will contribute to the understanding and treatment of HPV related diseases but is not sufficiently power for these endpoints. The strength of this trial is that it is a double blind- placebo controlled adequately power trial with long-term follow-up to measure effect on recurrent-relapsing CIN II-III.

CIN

:   Cervical Intraepithelial Neoplasia

LSIL

:   Low-grade squamous intraepithelial lesion

HSIL

:   High-grade squamous intraepithelial lesion

HPV

:   Human Papillomavirus

hrHPV

:   High risk Human Papillomavirus

LEEP

:   Loop Electrosurgical Excision Procedure

iPCQ

:   iMTA Productivity Cost Questionnaire

iMCQ

:   iMTA Medical Consumption Questionnaire
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